Unit:
Κατεύθυνση Παθολογία της ΚύησηςLibrary of the School of Health Sciences
Supervisors info:
Εμμανουήλ Σαλαμαλέκης, Δημήτριος Κασσάνος, Χαράλαμπος Συριστατίδης
Original Title:
Καρκίνος μαστού στη κύηση και γονιμότητα
Summary:
Breast cancer is the second leading cause of death from cancer in women during
pregnancy. Pregnancy-associated breast cancer (PABC) presents a challenging
clinical situation because of the special and unique circumstances surrounding
the growth and differentiation of the developing fetus.
The management of a woman with breast cancer in pregnancy should be
performed by a multidisciplinary team comprising of an
obstetrician-gynecologist, an oncology surgeon, a radiotherapist, a
chemotherapist and a specially trained oncology nurse.
Surgical treatment can be safely performed during pregnancy. Chemotherapy
should be postponed until the second or third trimester of pregnancy, while the
radiotherapy should be applied during the postpartum period. The majority of
patients require chemotherapy, but the time of onset, compared with childbirth
requires special and personalized approach and carefully considerations.
The use of targeted therapy and adjuvant hormone therapy is not yet eligible
for the treatment of breast cancer during pregnancy. The administration of
tamoxifen has been implicated teratogenicity, and therefore considered prudent
to delay until the end of pregnancy. Similarly, administration of targeted
therapy (trastuzumad) can not be recommended with safety, during pregnancy.
Keywords:
Breast cancer, Breast, Pregnancy, Fertility, Breast-feeding
Number of references:
165
File:
File access is restricted only to the intranet of UoA.
document.pdf
2 MB
File access is restricted only to the intranet of UoA.